Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An open-label trial of the PPARgamma ligand rosiglitazone for active ulcerative colitis

Lewis, James D., Lichtenstein, Gary R., Stein, Robert B., Deren, Julius J., Judge, Thomas A., Fogt, Franz, Furth, Emma E., Demissie, E.J., Hurd, Linda B., Su, Chinyu G., Keilbaugh, Sue A., Lazar, Mitchell A., Wu, Gary D.·2001·The American Journal of Gastroenterology

Abstract

OBJECTIVES: Previous research has demonstrated that ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARs) reduce inflammation in two different murine models of colitis. This study was designed to examine the potential efficacy of rosiglitazone, a ligand for the gamma subtype of PPARs, as a therapy for active ulcerative colitis. METHODS: Fifteen patients with mild to moderately active ulcerative colitis despite therapy with 5-aminosalicylic acid compounds were enrolled in an open-label study of rosiglitazone (4 mg b.i.d. p.o.) for 12 wk. Thirteen of 15 patients were receiving concomitant therapy with corticosteroids and/or immunomodulator medications. Disease activity was measured with the Disease Activity Index. RESULTS: After 12 wk of therapy, four patients (27%) had achieved clinical remission, of whom three (20%) also had an endoscopic remission. Four additional patients (27%) had a clinical response without achieving remission. Two patients were hospitalized with worsened disease activity, and one patient was withdrawn for nephrotic syndrome. CONCLUSIONS: These data suggest that ligands for the gamma subtype of PPARs may represent a novel therapy for ulcerative colitis. A double blind, placebo-controlled, randomized trial is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2001.05333.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 181

Metadata

Authors
Lewis, J. D., Lichtenstein, G. R., Stein, R. B., Deren, J. J., Judge, T. A., Fogt, F., Furth, E. E., Demissie, E. J., Hurd, L. B., Su, C. G., Keilbaugh, S. A., Lazar, M. A., & Wu, G. D.
Venue
The American Journal of Gastroenterology
Published
2001-12
Volume
96
Issue
12
Pages
3323-3328
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W2115518955
Cited by
181
References
1
FWCI
7.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An open-label trial of the PPARgamma ligand rosiglitazone for active ulcerative colitis. https://app.cochat.ai/papers/10.1111/j.1572-0241.2001.05333.x
The paper
Lewis, J. D., Lichtenstein, G. R., Stein, R. B., Deren, J. J., Judge, T. A., Fogt, F., Furth, E. E., Demissie, E. J., Hurd, L. B., Su, C. G., Keilbaugh, S. A., Lazar, M. A., & Wu, G. D. (2001). An open-label trial of the PPARgamma ligand rosiglitazone for active ulcerative colitis. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2001.05333.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.